Foundry Partners LLC Boosts Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Foundry Partners LLC lifted its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 3.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,781 shares of the specialty pharmaceutical company’s stock after buying an additional 509 shares during the quarter. Foundry Partners LLC’s holdings in Collegium Pharmaceutical were worth $610,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. ProShare Advisors LLC lifted its position in shares of Collegium Pharmaceutical by 3.3% during the first quarter. ProShare Advisors LLC now owns 8,826 shares of the specialty pharmaceutical company’s stock worth $343,000 after acquiring an additional 281 shares in the last quarter. Louisiana State Employees Retirement System boosted its stake in Collegium Pharmaceutical by 1.9% in the 2nd quarter. Louisiana State Employees Retirement System now owns 16,500 shares of the specialty pharmaceutical company’s stock worth $531,000 after purchasing an additional 300 shares during the period. SummerHaven Investment Management LLC grew its holdings in Collegium Pharmaceutical by 1.3% during the 2nd quarter. SummerHaven Investment Management LLC now owns 34,773 shares of the specialty pharmaceutical company’s stock valued at $1,120,000 after buying an additional 452 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Collegium Pharmaceutical by 1.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,282 shares of the specialty pharmaceutical company’s stock valued at $1,137,000 after buying an additional 535 shares in the last quarter. Finally, CWM LLC lifted its holdings in shares of Collegium Pharmaceutical by 97.5% in the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock worth $58,000 after buying an additional 736 shares in the last quarter.

Collegium Pharmaceutical Stock Down 1.5 %

COLL opened at $29.96 on Friday. The business’s fifty day simple moving average is $35.84 and its 200 day simple moving average is $34.82. Collegium Pharmaceutical, Inc. has a 52 week low of $25.16 and a 52 week high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The stock has a market cap of $966.21 million, a PE ratio of 12.91 and a beta of 0.95.

Analysts Set New Price Targets

A number of research firms recently weighed in on COLL. Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Piper Sandler reaffirmed a “neutral” rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 11th. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. HC Wainwright upped their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, September 5th. Finally, Truist Financial lifted their price target on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $42.60.

Insider Transactions at Collegium Pharmaceutical

In related news, EVP Thomas B. Smith sold 9,593 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the completion of the sale, the executive vice president now owns 53,816 shares in the company, valued at $1,970,741.92. The trade was a 15.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total transaction of $737,198.40. Following the transaction, the executive vice president now owns 120,161 shares in the company, valued at $4,602,166.30. The trade was a 13.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.